Antibodies for treatment of Clostridium difficile infection.
Antibodies for the treatment of Clostridium difficile infection (CDI) have been demonstrated to be effective in the research and clinical environments. Early uncertainties about molecular and treatment modalities now appear to have converged upon the systemic dosing of mixtures of human IgG1. Although multiple examples of high-potency monoclonal antibodies (MAbs) exist, significant difficulties were initially encountered in their discovery. This minireview describes historical and contemporary MAbs and highlights differences between the most potent MAbs, which may offer insight into the pathogenesis and treatment of CDI.
UCB-Pharma, Slough, United Kingdom david.humphreys@ucb.com.
David P
DP
Humphreys
Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom.
Mark H
MH
Wilcox
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000276:immunology*; D004761:Enterocolitis, Pseudomembranous / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D007074:Immunoglobulin G